Intellia Therapeutics

NTLA

Market cap $1.45B

Intellia Therapeutics, Inc. (NTLA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Intellia Therapeutics, Inc. (NTLA) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, NTLA broke through the 200-day moving average, which suggests a long-term bullish trend.

The president and CEO of Intellia Therapeutics sold 34,146 directly held shares of the firm on Jan. 5. The sale represented 3.09% of John M.

CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the company will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2026 at 9:00 a.m. PT.

NTLA shares plunge 55% in three months after the FDA placed a clinical hold on Nex-Z, suspending trials and milestone guidance following the death of a patient.

A clinical hold and a complex commercial path make Intellia Therapeutics' outlook uncertain. Despite steadily growing revenue, Iovance Biotherapeutics faces nearly insurmountable challenges.

CAMBRIDGE, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on December 1, 2025, it awarded inducement grants to three new employees under Intellia's 2024 Inducement Plan as a material inducement to employment.

Intellia advances in vivo pipeline with lonvo-z through its pivotal HAELO study, eyeing mid-2026 data and a potential 2026 filing to propel growth.

Beam's broad early-stage pipeline and recent study progress take center stage as investors weigh its potential against rival NTLA's prospects.

Traders like heavily shorted stocks for two main reasons: either to bet on a decline in the company's value, or to profit from a short squeeze.